Venetoclax Plus Rituximab: ' Unprecedented ' Efficacy in CLL Venetoclax Plus Rituximab: ' Unprecedented ' Efficacy in CLL
A new chemo-free combination, venetoclax and rituximab, has shown complete response rates in half of patients with refractory or relapsed chronic lymphocytic leukemia (CLL).Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia | Pathology | Rituxan